Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma

Inclusion Criteria

• •Patients aged ≥ 18 years old
• •Eastern Cooperative Oncology Group (ECOG) performance 0 to 1
• •Confirmed diagnosis of Hepatocellular carcinoma (HCC)
• •Tumour size ≥ 3cm
• •Patients planning on undergoing Stereotactic Body Radiation Therapy (SBRT) for HCC
• •Prior radiofrequency ablation at a different site, or prior surgery are eligible
• •Child-Pugh A liver function
• •Life expectancy longer than 12 weeks
• •At least one measurable treatment lesion according to RECIST 1.1
• •Written informed consent must be obtained prior to any study related procedures
• •Adequate haematological function (Hemoglobin ≥ 8.5g/dL; Platelet Count ≥ 75x109/L; Antenatal Care ≥ 1.5x109/L; international normalised ratio ≤ 1.5)
• •Adequate hepatic function (albumin ≥ 28g/l; Bilirubin ≤ 1.5xULN; Alanine transaminase \< 5 times upper limit normal)
• •Adequate renal function (serum creatinine ≤ 1.5 times the upper limit of normal range; Sodium ≥ 130mmol/L; Potassium ≥ 3.0mmol/L)
• •Able to read, understand and provide written consent